PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Revenue of PROCEPT BioRobotics Corporation (PRCT)
Revenue in 2023 (TTM): $136.19 M
According to PROCEPT BioRobotics Corporation's latest financial reports the company's current revenue (TTM) is $136.19 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of PROCEPT BioRobotics Corporation
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $136.19 M | $71.05 M | $-98,095,000 | $-105,897,000 | $-105,897,000 |
| 2022 | $75.01 M | $37.09 M | $-77,652,000 | $-87,154,000 | $-93,584,000 |
| 2021 | $34.47 M | $15.87 M | $-51,064,000 | $-59,853,000 | $-62,384,000 |
| 2020 | $7.72 M | $-1,255,000 | $-45,055,000 | $-53,019,000 | $-58,255,000 |
| 2019 | $6.17 M | $-1,885,000 | $-39,757,000 | $-41,975,000 | $-42,653,000 |